Deramiocel
- Generic Name
- Deramiocel
Intravenous Infusion of CAP-1002 in Patients With COVID-19
Phase 2
Completed
- Conditions
- Covid19
- Interventions
- Biological: PlaceboBiological: CAP-1002
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Capricor Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04623671
- Locations
- ๐บ๐ธ
Cedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธUniversity of California Davis, Sacramento, California, United States
๐บ๐ธHenry Ford Health System, Detroit, Michigan, United States
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Phase 2
Completed
- Conditions
- Muscular DystrophiesGenetic Diseases, InbornMuscular DiseasesNervous System DiseasesGenetic Diseases, X-LinkedMuscular Dystrophy, DuchenneNeuromuscular DiseasesMuscular Disorders, Atrophic
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Capricor Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03406780
- Locations
- ๐บ๐ธ
University of California, Davis, Sacramento, California, United States
๐บ๐ธChildren's Hospital Colorado, Aurora, Colorado, United States
๐บ๐ธNemours Children's Hospital, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath